Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653492 · ClinicalTrials.gov registry record · Phase 2
Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease
A Phase 2 study of Pediatric Kidney Disease, sponsored by University of Rochester.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05653492: Active Phase 2 study of Pediatric Kidney Disease, sponsored by University of Rochester.
NCT05653492 is a Phase 2 study of Pediatric Kidney Disease that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 12 participants, below the 5,198-participant average among 4 other Pediatric Kidney Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05653492, a Phase 2 study of Pediatric Kidney Disease, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.
Conditions Studied
Interventions
- DRUG Sulforaphane
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05653492 still lists
NCT05653492 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 5,198-participant average among 4 other Pediatric Kidney Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Pediatric Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Sulforaphane is the first listed.
NCT05653492 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05653492 about?
NCT05653492 is a clinical study titled "Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease". This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include prelim...
What is the current status of trial NCT05653492?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-05-15. Estimated completion is 2025-12-31.
What conditions does trial NCT05653492 study?
This clinical trial studies the following conditions: Pediatric Kidney Disease.
What interventions are being tested in trial NCT05653492?
The interventions under investigation include: Sulforaphane (DRUG).
Who is sponsoring clinical trial NCT05653492?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653492 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
RECRUITING · Early Phase 1
-
VIRTUUS Children's Study
ACTIVE NOT RECRUITING
-
Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management
COMPLETED · NA
-
Preserving Kidney Function in Children With Chronic Kidney Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI